Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.

Molecular cancer research : MCR - 1 Jan 2011

Petroni Marialaura, Veschi Veronica, Prodosmo Andrea, Rinaldo Cinzia, Massimi Isabella, Carbonari Maurizio, Dominici Carlo, McDowell Heather P, Rinaldi Christian, Screpanti Isabella, Frati Luigi, Bartolazzi Armando, Gulino Alberto, Soddu Silvia, Giannini Giuseppe

Abstract excerpt

MYCN amplification occurs in approximately 20% of human neuroblastomas and is associated with early tumor progression and poor outcome, despite intensive multimodal treatment. However, MYCN overexpression also sensitizes neuroblastoma cells to apoptosis. Thus, uncovering the molecular mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bleomycin

Share to N-Myc Proto-Oncogene Protein

Share to Neuroblastoma

Share to Oncogene Proteins

Share to RNA Interference

Share to Serine

Source

Identifiers

PMID: 21173028
DOI: 10.1158/1541-7786.MCR-10-0227

Genes

MYCN
HIPK2
ATM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21173028-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.PMID 21173028Read ↗

Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.Semantic proximity Read ↗

Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma CellsSemantic proximity Read ↗

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.Semantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaSemantic proximity Read ↗

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In VivoSemantic proximity Read ↗

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastomaSemantic proximity Read ↗

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationSemantic proximity Read ↗

HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITASemantic proximity Read ↗

Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor CellsSemantic proximity Read ↗

Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosisSemantic proximity Read ↗

Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.